Cronos Group Reports Record Q1 2026 Revenue and Profit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Should l Buy CRON?
Source: Newsfilter
- Significant Revenue Growth: In Q1 2026, Cronos Group achieved net revenue of $45.2 million, a 40% year-over-year increase, primarily driven by strong sales in Israel and other countries, highlighting the company's robust growth potential in international markets.
- Improved Gross Margin: The gross profit for Q1 was $19.2 million, reflecting a 39% increase from the previous year, driven by higher average sales prices and increased sales volumes, further solidifying the company's competitive position in the market.
- Leading Market Share: The Spinach® brand captured the #1 position in the Canadian vape market for the first time with a 9.8% market share, while maintaining its top position in edibles, showcasing the strength of its brand portfolio and innovation capabilities.
- Strong Financial Position: As of Q1 2026, Cronos Group reported cash and cash equivalents of $822 million, demonstrating the company's financial strength and flexibility for future investments and expansions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.570
Low
2.30
Averages
2.72
High
3.14
Current: 2.570
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cronos Group Reports Record Q1 2026 Revenue and Profit
- Significant Revenue Growth: In Q1 2026, Cronos Group achieved net revenue of $45.2 million, a 40% year-over-year increase, primarily driven by strong sales in Israel and other countries, highlighting the company's robust growth potential in international markets.
- Improved Gross Margin: The gross profit for Q1 was $19.2 million, reflecting a 39% increase from the previous year, driven by higher average sales prices and increased sales volumes, further solidifying the company's competitive position in the market.
- Leading Market Share: The Spinach® brand captured the #1 position in the Canadian vape market for the first time with a 9.8% market share, while maintaining its top position in edibles, showcasing the strength of its brand portfolio and innovation capabilities.
- Strong Financial Position: As of Q1 2026, Cronos Group reported cash and cash equivalents of $822 million, demonstrating the company's financial strength and flexibility for future investments and expansions.
See More
Cronos Group Reports First Quarter Earnings Growth
- Significant Earnings Increase: Cronos Group reported a first-quarter profit of $13.75 million, translating to $0.04 per share, a substantial rise from last year's $6.12 million and $0.02 per share, indicating a marked improvement in the company's profitability.
- Strong Revenue Growth: The company's revenue surged by 40.1% to $45.21 million compared to $32.26 million last year, reflecting robust market demand and the effectiveness of its sales strategies.
- Market Performance Recovery: With both revenue and earnings growth, Cronos Group demonstrates stronger resilience in a competitive market, potentially attracting more investor interest in its future growth prospects.
- Improved Financial Health: The ongoing revenue and profitability enhancements suggest that Cronos Group's financial health is improving, laying a solid foundation for future expansion and investment opportunities.
See More
Cronos Group to Announce Q1 Earnings on May 11
- Earnings Announcement: Cronos Group is set to release its Q1 2023 earnings on May 11 before market open, with consensus EPS estimated at $0.01 and revenue projected at $42.29 million, reflecting a robust 31.1% year-over-year growth that will provide critical insights into the company's financial health.
- Positive Market Reaction: Cannabis stocks are experiencing a surge following the DEA's rescheduling move, and as a key player in the industry, Cronos may benefit from heightened market sentiment, potentially driving its stock price upward.
- International Expansion Strategy: Cronos is actively pursuing its European expansion and aims to stabilize margins through the acquisition of CanAdelaar, a strategy that will enhance its competitiveness in international markets and support sustainable growth.
- Strong Financial Position: Despite market fluctuations, Cronos Group maintains a strong balance sheet, indicating its relative undervaluation in the industry, which is likely to attract increased investor interest moving forward.
See More
Cronos Launches New Spinach STIX® Pre-Rolls Across Canada
- Growing Market Demand: Spinach STIX®, Cronos' latest cylindrical pre-roll, is designed to meet surging consumer interest in this popular format, with the pre-roll category accounting for over 33% of retail sales in the Canadian cannabis market, indicating strong market potential.
- Impressive Sales Figures: In March 2026, cylindrical pre-rolls generated over $17 million in Canadian retail sales, reflecting consumer preferences for portable, even-burning, and smooth smoking experiences, which further drives growth in this category.
- Product Expansion Strategy: Spinach STIX® is now available in multiple provinces including Alberta, British Columbia, and Manitoba, aiming to meet evolving consumer preferences by offering a sleeker pre-roll option, thereby enhancing the brand's competitive position in the market.
- Strengthening Brand Positioning: Cronos is focused on optimizing its high-quality product lineup, positioning Spinach® as one of the most reliable cannabis brands in Canada, thereby solidifying its leadership in the rapidly growing market.
See More
Cronos Group Announces 2026 Annual Shareholders Meeting Details
- Meeting Schedule: Cronos Group will hold its 2026 Annual Meeting of Shareholders on June 18, 2026, at 11:00 a.m. ET in a virtual format, ensuring equal participation for all registered shareholders and proxyholders.
- Participation Details: The meeting will be conducted via live audio webcast, allowing shareholders to ask questions and vote online, which enhances shareholder engagement and interaction, thereby improving corporate governance transparency.
- Replay Availability: A replay of the meeting will be accessible approximately 24 hours after its conclusion in the investor relations section of the company's website, ensuring that shareholders who could not attend live can still access the meeting content.
- Company Overview: Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation, aiming to build an iconic brand portfolio to elevate the consumer experience.
See More
U.S. Places Medical Cannabis Products in Schedule III
- Policy Impact: The U.S. government's decision to place FDA-approved marijuana products and state-licensed medical cannabis programs into Schedule III is expected to facilitate clinical research and broaden treatment access, thereby enhancing the legitimacy of medical cannabis in modern healthcare.
- Tilray's Expansion Plans: Tilray is exploring participation in a federal pilot program run by the Center for Medicare and Medicaid Innovation, aiming to supply hemp-derived medical cannabis through cancer clinics, which is intended to improve services for underserved patients.
- Market Reaction Volatility: Although Tilray's stock surged by 19% following the policy announcement, it ultimately closed down 12%, reflecting investor concerns over the limited scope of the order, which also negatively impacted other cannabis companies' stock prices.
- Optimistic Industry Outlook: Roth Capital Partners views the partial rescheduling order as “extremely favorable,” potentially alleviating Section 280E tax restrictions, improving import and export prospects, and paving the way for eventual adult-use rescheduling, thus enhancing overall sector investability.
See More
Cronos Group Reports Record Q1 2026 Revenue and Profit
- Significant Revenue Growth: In Q1 2026, Cronos Group achieved net revenue of $45.2 million, a 40% year-over-year increase, primarily driven by strong sales in Israel and other countries, highlighting the company's robust growth potential in international markets.
- Improved Gross Margin: The gross profit for Q1 was $19.2 million, reflecting a 39% increase from the previous year, driven by higher average sales prices and increased sales volumes, further solidifying the company's competitive position in the market.
- Leading Market Share: The Spinach® brand captured the #1 position in the Canadian vape market for the first time with a 9.8% market share, while maintaining its top position in edibles, showcasing the strength of its brand portfolio and innovation capabilities.
- Strong Financial Position: As of Q1 2026, Cronos Group reported cash and cash equivalents of $822 million, demonstrating the company's financial strength and flexibility for future investments and expansions.
See More
Cronos Group Reports First Quarter Earnings Growth
- Significant Earnings Increase: Cronos Group reported a first-quarter profit of $13.75 million, translating to $0.04 per share, a substantial rise from last year's $6.12 million and $0.02 per share, indicating a marked improvement in the company's profitability.
- Strong Revenue Growth: The company's revenue surged by 40.1% to $45.21 million compared to $32.26 million last year, reflecting robust market demand and the effectiveness of its sales strategies.
- Market Performance Recovery: With both revenue and earnings growth, Cronos Group demonstrates stronger resilience in a competitive market, potentially attracting more investor interest in its future growth prospects.
- Improved Financial Health: The ongoing revenue and profitability enhancements suggest that Cronos Group's financial health is improving, laying a solid foundation for future expansion and investment opportunities.
See More
Cronos Group to Announce Q1 Earnings on May 11
- Earnings Announcement: Cronos Group is set to release its Q1 2023 earnings on May 11 before market open, with consensus EPS estimated at $0.01 and revenue projected at $42.29 million, reflecting a robust 31.1% year-over-year growth that will provide critical insights into the company's financial health.
- Positive Market Reaction: Cannabis stocks are experiencing a surge following the DEA's rescheduling move, and as a key player in the industry, Cronos may benefit from heightened market sentiment, potentially driving its stock price upward.
- International Expansion Strategy: Cronos is actively pursuing its European expansion and aims to stabilize margins through the acquisition of CanAdelaar, a strategy that will enhance its competitiveness in international markets and support sustainable growth.
- Strong Financial Position: Despite market fluctuations, Cronos Group maintains a strong balance sheet, indicating its relative undervaluation in the industry, which is likely to attract increased investor interest moving forward.
See More
Cronos Launches New Spinach STIX® Pre-Rolls Across Canada
- Growing Market Demand: Spinach STIX®, Cronos' latest cylindrical pre-roll, is designed to meet surging consumer interest in this popular format, with the pre-roll category accounting for over 33% of retail sales in the Canadian cannabis market, indicating strong market potential.
- Impressive Sales Figures: In March 2026, cylindrical pre-rolls generated over $17 million in Canadian retail sales, reflecting consumer preferences for portable, even-burning, and smooth smoking experiences, which further drives growth in this category.
- Product Expansion Strategy: Spinach STIX® is now available in multiple provinces including Alberta, British Columbia, and Manitoba, aiming to meet evolving consumer preferences by offering a sleeker pre-roll option, thereby enhancing the brand's competitive position in the market.
- Strengthening Brand Positioning: Cronos is focused on optimizing its high-quality product lineup, positioning Spinach® as one of the most reliable cannabis brands in Canada, thereby solidifying its leadership in the rapidly growing market.
See More
Cronos Group Announces 2026 Annual Shareholders Meeting Details
- Meeting Schedule: Cronos Group will hold its 2026 Annual Meeting of Shareholders on June 18, 2026, at 11:00 a.m. ET in a virtual format, ensuring equal participation for all registered shareholders and proxyholders.
- Participation Details: The meeting will be conducted via live audio webcast, allowing shareholders to ask questions and vote online, which enhances shareholder engagement and interaction, thereby improving corporate governance transparency.
- Replay Availability: A replay of the meeting will be accessible approximately 24 hours after its conclusion in the investor relations section of the company's website, ensuring that shareholders who could not attend live can still access the meeting content.
- Company Overview: Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation, aiming to build an iconic brand portfolio to elevate the consumer experience.
See More
U.S. Places Medical Cannabis Products in Schedule III
- Policy Impact: The U.S. government's decision to place FDA-approved marijuana products and state-licensed medical cannabis programs into Schedule III is expected to facilitate clinical research and broaden treatment access, thereby enhancing the legitimacy of medical cannabis in modern healthcare.
- Tilray's Expansion Plans: Tilray is exploring participation in a federal pilot program run by the Center for Medicare and Medicaid Innovation, aiming to supply hemp-derived medical cannabis through cancer clinics, which is intended to improve services for underserved patients.
- Market Reaction Volatility: Although Tilray's stock surged by 19% following the policy announcement, it ultimately closed down 12%, reflecting investor concerns over the limited scope of the order, which also negatively impacted other cannabis companies' stock prices.
- Optimistic Industry Outlook: Roth Capital Partners views the partial rescheduling order as “extremely favorable,” potentially alleviating Section 280E tax restrictions, improving import and export prospects, and paving the way for eventual adult-use rescheduling, thus enhancing overall sector investability.
See More
